[Skip to Content]
[Skip to Content Landing]
Views 161
Citations 0
Editor's Correspondence
Oct 22, 2012

What Is More Valuable: Fenofibrate Patents or Fenofibrate Clinical Outcomes?

Author Affiliations

Author Affiliation: Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles.

Arch Intern Med. 2012;172(19):1521-1522. doi:10.1001/archinternmed.2012.4386

Downing et al1 present the opinion that Abbott's various brands of fenofibrate and fenofibric acid inappropriately manipulated the patent and drug approval process to protect brand profits. However, it is likely that Abbott would have provided substantial confidential rebates and discounts for its various branded fenofibrate products to maintain favorable formulary status and market share. Absent this and other confidential trial document information, it is impossible to know if and how much consumers were actually harmed by Abbott's alleged behavior.